Posts

Posted on

BevCanna Provides Update on Commercialization Plans and Landmark Proposed Acquisition of Naturo Group

BevCanna Provides Update on Commercialization Plans and Landmark Proposed Acquisition of Naturo Group

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201127005224/en/

BevCanna provided updates on the following:

  • The Company announced the landmark proposed acquisition of established beverage manufacturer and BevCanna partner Naturo Group Investments Inc. (“Naturo”). The proposed combination will create the only fully licensed white-label beverage manufacturing and distribution company with the capability to manufacture and distribute both CPG and cannabis-based beverages, with a global multi-channel distribution network of traditional retail and cannabis sales channels.
  • Naturo brings over C$35M in assets, including the 40,000 sq. ft. beverage facility, 315-acres of cultivatable land valued at C$10.4M, beverage manufacturing equipment valued C$3.4M as of year-end and Naturo’s exclusive onsite alkaline spring water source, independently valued at C$18M. Naturo’s latest independent estimate of enterprise value is C$38M-C$42 (February 2020).
  • Naturo also brings the nationally distributed Naturo flagship brand, TRACE, which currently enjoys a leadership position within the Canadian fulvic/humic plant-based functional mineral category and is sold in more than 3,000 Canadian retail stores, with select international agreements and partnerships under review.
  • The agreement will eliminate future payment liabilities under BevCanna’s current lease agreement, royalty agreement and manufacturing agreements with Naturo. These eliminated agreements and fees will preserve future working capital and allow BevCanna to direct more resources towards its operations and shareholder value.
  • The proposed company will combine the decades of consumer-packaged goods (“CPG”), capital markets, corporate strategy and public company expertise of both operational teams.
  • Recent developments and initiatives related to Pure Therapy, BevCanna’s U.S. natural health and wellness direct to consumer e-commerce operation.
  • The Company’s commercialization plans for the launch of the award-winning Keef and Cali-Bloom cannabis brands in the Canadian market, as well as the Company’s white-label operations, in anticipation of the imminent receipt of BevCanna’s Standard Processing License (SPL). The SPL is in the final review stage and the Company is in active discussions with Health Canada.

To access the call replay by telephone: Dial 1-800-319-6413 and use the passcode 5703#.

The replay of the audio call will be available until end of day December 1, 2020.

To access the call replay through the web: http://services.choruscall.ca/links/bevcanna20201124.html

The webcast will be available until end of day February 24, 2021.

View a replay of BevCanna CEO Marcello Leone’s Monday November 23, 2020 broadcast feature on BNN Bloomberg. BevCanna CEO Marcello Leone is interviewed on BevCanna’s strategy, upcoming launch in the Canadian cannabis market and progress on its international initiatives. BNN Bloomberg reaches more than 982,000 weekly through its national broadcast program and partner sites.

About BevCanna Enterprises Inc.

BevCanna Enterprises Inc. (CSE: BEV, OTCQB:BVNNF, FSE:7BC) develops and manufactures cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients. With decades of experience creating, branding and distributing iconic brands that have resonated with consumers on a global scale, the team demonstrates an expertise unmatched in the emerging cannabis beverage category. Based in British Columbia, Canada, BevCanna owns the exclusive rights to a pristine spring water aquifer, access to a world‐class 40,000‐square‐foot, HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum. BevCanna also recently acquired U.S. natural health and wellness e-commerce platform Pure Therapy. BevCanna’s vision is to be a global leader in infused innovations.

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including the statements regarding: the terms of the proposed acquisition of Naturo (the “Transaction”); that the parties will enter into the definitive agreement regarding the Transaction; the future business plans of Naturo and BevCanna; and the perceived benefits of combining the businesses of Naturo and BevCanna; the Company’s commercialization plans for the launch of the award-winning Keef and Cali-Bloom cannabis brands in the Canadian market, as well as the Company’s white-label operations, in anticipation of the imminent receipt of BevCanna’s Standard Processing License (SPL); and other statements regarding the business plans of the Company.

Forward-looking statements are based on certain assumptions regarding the completion of the Transaction; the issuances of licences by Health Canada to the Company under the Cannabis Act; future positive legislative, tax and regulatory developments in the United States with respect to cannabis; a continued high regulatory barrier entry for cannabis-infused beverages; successful and timely commercialization of the company’s products; successful and timely negotiation of various agreements; and expectations with respect to the future growth of recreational cannabis products. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. The assumptions of the Company, although considered reasonable by it at the time of preparation, may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, the Transaction not being completed at all or on the terms announced; the Company not being issued licenses by Health Canada; risks associated with general economic conditions; risks associated with climate and agriculture; changes in consumer preferences; adverse industry events; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; the inability to enter into various agreements with other parties; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of the Company which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

On behalf of the Board of Directors:

John Campbell, Chief Financial Officer and Chief Strategy Officer

Director, BevCanna Enterprises Inc.

For media enquiries or interviews, please contact:

Wynn Theriault, Thirty Dash Communications

416‐710‐3370

[email protected]

For investor inquiries, please contact:

Luca Leone, BevCanna Enterprises Inc.

604‐880‐6618

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Retail Alternative Medicine Health Food/Beverage

MEDIA:

Logo
Logo
Posted on

Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years

Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years

– The combination therapy is a new treatment option for CF patients who are homozygous for F508del –

– The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations –

LONDON–(BUSINESS WIRE)–
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations in the CFTR gene that result in residual CFTR activity: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

“With this approval, children with CF in Europe ages 6 to 11 years with the most common mutation, F508del, have a new treatment option and children with certain residual function mutations will, for the first time, have a treatment option available that addresses the underlying cause of their CF,” said Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex. “Today’s approval brings us closer to our ultimate goal of providing medicines for all people with CF.”

SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor) will be immediately available to additional eligible patients in Germany and will be available shortly in countries that have entered into innovative long-term reimbursement agreements with Vertex, including the UK, Denmark and the Republic of Ireland. In all other countries, Vertex will work closely with relevant authorities in Europe to secure access for eligible patients.

In Europe, SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor) is already approved for the treatment of people with CF ages 12 years and older who have either two copies of the F508del mutation in the CFTR gene, or one copy of the F508del mutation and a copy of one of the following 14 mutations in which the CFTR gene results in residual CFTR protein activity: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

About Cystic Fibrosis

Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About SYMKEVI® in combination with KALYDECO®

Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information including dosing guidance, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Dr. Reshma Kewalramani in this press release, statements regarding the eligible patient population in Europe, our expectations regarding the timing of access to SYMKEVI in combination with KALYDECO for eligible patients ages 6-11 years across countries in Europe, and our plans to secure access to SYMKEVI in combination with KALYDECO for additional eligible patients ages 6-11 years in Europe. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, risks related to commercializing SYMKEVI in combination with KALYDECO in Europe, and other risks listed under Risk Factors in Vertex’s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated

Investors:

[email protected]

or

617-961-7163

Media:

[email protected]

or

International: +44 20 3204 5275

or

U.S.: 617-341-6992

KEYWORDS: Europe United States United Kingdom North America Massachusetts

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Health Children Genetics Consumer

MEDIA:

Logo
Logo
Posted on

REPLY: Reply enters into eSports

REPLY: Reply enters into eSports

TURIN, Italy–(BUSINESS WIRE)–
Reply, on the eve of Milan Games Week, announces its entry into eSports in collaboration with Totem eSports, a project born in 2019 that spent the year battling its way through the most competitive titles of the main ESL circuits, which for the 2021 season will be renamed Reply Totem eSports.

The Reply Totem eSports team, thanks to the experience gained by its young talents at national and international level, will compete in the next season in the ESL EVC circuits on the mobile titles including Clash Royale, Brawl Stars and on a series of other titles, ranging from sports such as FIFA to FPS and strategic cards.

Reply’s entry into eSports is part of a wider range of initiatives aimed at supporting young technology enthusiasts. With this collaboration, Reply, which already operates in the gaming sector with Game Studio and B2B initiatives, enters a market in continuous growth, that symbolizes the impact of digitalization in all sectors.

Filippo Rizzante, Reply’s CTO, commented: “The eSports sector shares values underpinning Reply’s corporate culture. With Reply Totem eSports we are pursuing a journey, which we are sure will further support the growth of the sector. Moreover, we are proud to support young people who have decided to turn their passion for video games and technology into a profession and we hope that their talent and successes will be an inspiration for all enthusiasts who share the same ideals.”

REPLY

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Reply

Fabio Zappelli

[email protected]

Tel. +390117711594

Aaron Miani

[email protected]

Tel. +3902535761

KEYWORDS: Italy Europe

INDUSTRY KEYWORDS: Sports Electronic Games Entertainment Other Sports General Sports

MEDIA:

Logo
Logo
Posted on

From Sketch to IoT Application with M5Paper – Touch Enabled e-ink Device

M5Paper is a touch-enabled E-ink display.

Shenzhen, Nov. 26, 2020 (GLOBE NEWSWIRE) — M5Stack has launched a unique new device in its core series. M5Paper is a touch-enabled E-ink display. Far from being a simple E-reader, M5Paper is a fully programmable microcontroller that could be the ideal choice for your IoT applications. This low power device could suit such purposes as a shelf display, industrial controller, smart weather display and so on. 

 

M5Paper is powered by the ESP32-D0WD. Its E-Ink display supports a 16-level grayscale, which provides a great reading experience. The display is a GT911 capacitive touch screen, which supports multipoint touch and a variety of gesture controls.

 

Compared to a regular LCD, E-Ink displays are easier on the eyes, which makes them a great choice for reading or viewing for longer periods. The M5Paper has ultra-low power consumption, basically, power is only required for refreshing and keeps displaying previous content for a long time even when powered down.

Similar to the M5Stack Core Ink, it is equipped with multi-function buttons for operation, sensors such as the SHT30 temperature and moisture sensor and an SD card port for data storage.

Additionally, the FM24C02 internal EEPROM chip (256KB-EEPROM) can be used to store vital data even when the device is off. A 1150mAh lipo battery keeps the device going for long periods and battery life can be further preserved by using the RTC (BM8563) to set the device into a deep sleep and wake it up again when needed. Three HY2.0-4P expansion ports are included which allow for building complex projects using the existing sensors in the M5Stack ecosystem.

Product Features

ESP32 Standard Wireless Functions WiFi, Bluetooth Internal 16M Flash

Ultra-Low Power Consumption

Multi-Point Touch Screen

180 Degree Viewing Angle

Internal 1150mAh Battery

Expandable – HY2.0-4P 3 x External Expansion Ports

 

Applications

IoT Terminal

E-Book Reader

Industrial Control Panel 

Smart Home Panel

 

M5Paper is compatible with Arduino, MicroPython, and UIFlow. UIFlow is a Web-based IoT programming system developed by M5Stack and based on Google Blockly which is a clear and easy to program visual interface. 

 

If you require a smart display with minimal power consumption, M5Paper could very well be the device for you.

Attachments 



Diana
M5Stack
[email protected]

Posted on

YWCA Metro Vancouver welcomes Parliamentary Secretary for BC’s non-profit sector

VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) — YWCA Metro Vancouver welcomes the provincial government’s commitment to BC’s non-profit sector with the appointment of Niki Sharma as Parliamentary Secretary of Community Development and Non-Profits.

The appointment comes at a time when nearly one in four non-profits report being at risk of closing their doors as a result of COVID-19.

The non-profit sector is fundamental to BC, contributing $6.7 billion to the province’s GDP, employing 86,000 people and serving tens of thousands of British Columbians. Since the onset of the pandemic, YWCA Metro Vancouver, alongside its peers in the charitable and non-profit sector, have felt the brunt of increased demand on services combined with limited or reduced revenue streams.

As much as 23% of charities and non-profits in B.C. have said they are at risk of shutting down as a result of the pandemic, according to a recent survey undertaken by Vantage Point.

YWCA Metro Vancouver is projecting significant revenue losses in 2020 due to COVID-19’s impacts on its hotel and health and fitness centre, both of which help YWCA community programs. The decrease in demand in the hospitality and health and fitness sectors will also impact the YWCA’s capacity to deliver programs and services in 2021 and beyond.

Non-profits have been on the frontlines of the pandemic’s cascading effects, providing much-needed housing, child care, recovery and mental health services and food supports. The pandemic has also disproportionately impacted women through job and income loss, increased intimate partner violence and increased unpaid care work at home. As a result, the YWCA has stepped up its supports for single moms and women leaving violence.

YWCA Metro Vancouver CEO, Deb Bryant, says Sharma’s appointment is a win for the charitable and non-profit sector at a time when it is needed more than ever.

“If this year has shown us anything, it’s how vital frontline, community organizations are to our province. It’s great to see the government acknowledge that with the commitment of a Parliamentary Secretary and we look forward to working with Niki in the coming years.”

For media inquiries please contact:

Rebecca Savory, Communications Specialist
Email: [email protected]
Phone: 236 865 0849

YWCA Metro Vancouver is a registered charity, providing a range of integrated services for women and their families and those seeking to improve the quality of their lives. From early learning and child care to housing, health and fitness, employment services and leadership, the YWCA touches lives in our communities.

Learn More

For more information about vulnerability in BC’s charities and non-profits, see the No Immunity report Vancouver Foundation released earlier this year in partnership with Vantage Point, the City of Vancouver, and Victoria Foundation: https://www.thevantagepoint.ca/blog/no-immunity-impacts-covid-19-our-sector.



Posted on

A New Parliamentary Secretary Creates Positive Impact on Communities

Vantage Point congratulates Niki Sharma on being appointed Parliamentary Secretary for Community Development and Non-Profits and pledges its support for unleashing the potential of charities and nonprofits in BC’s recovery

VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) — Vantage Point’s Executive Director Alison Brewin congratulates Niki Sharma on being appointed Parliamentary Secretary for Community Development and Non-Profits today, and applauds Premier Horgan for his government’s commitment to cultivating a stronger relationship with BC’s charities and nonprofits.

Not-for-profits and charities have stepped into pandemic response over the past eight months with great resilience and creativity however, as shown in the No Immunity Report published earlier this year, 23% of charities and nonprofits said they’re at risk of closing their doors because of urgent threats caused by the pandemic—even as demand for their services is rising.

These organizations have been on the frontlines of providing critical services and maintaining resiliency throughout each wave of the virus. But now, with revenue and income shrinking, their very existence is at risk. We need to move quickly in collaboration to ensure these organizations can continue to action their missions and lift our communities while continuing to provide essential services and resources.

With the newly appointed Parliamentary Secretary, there is renewed ability to mobilize the not-for-profit and charitable sector’s 86,000 employees to even greater ability as the sector deals with challenges such as the overdose crisis, climate change, homelessness, and racial justice. Vantage Point looks forward to being able to collaborate with Parliamentary Secretary Sharma in leveraging the sector to continue to do this crucial work that contributes $6.7 billion to BC’s GDP and serves tens of thousands each year.

Vantage Point is excited to collaborate with Parliamentary Secretary Sharma to engage charities and nonprofits in key elements of the government’s Stronger BC recovery plan: a nimble workforce, expanded community infrastructure, and wraparound supports like childcare, mental health services, and food security initiatives. With this appointment the government is saying it understands the critical contribution this sector makes to the wellbeing of people and communities across the province.

Quote

Alison Brewin, Executive Director of Vantage Point

“This is an exciting decision of the government and one that can have deep and positive impact on communities, the economy
,
and the environment. It is a clear sign that the government seeks to partner with the sector to find solutions and build back better
together.
“

Learn More

About Vantage Point

Vantage Point exists to support the people moving these organizations forward – Executive Directors, board members, senior leaders, managers, staff, and volunteers. Our mission is to transform not-for-profit organizations by convening, connecting, and equipping leaders to lift organizational capacity. Every client leaves our programs with resources to excel in their role and grow the impact of their organization. thevantagepoint.ca

Media Contact

Nav Nagra, Communications and Inclusion Manager

Email:
Phone:		 [email protected]

604-562-4757



Posted on

Amorepacific Develops an Original Technology That Reverses the Aging of Skin Cells in Joint Research with KAIST

PR Newswire

SEOUL, South Korea, Nov. 26, 2020 /PRNewswire/ — Amorepacific R&D Center, together with KAIST, developed an original technology that reverses the aging process in human dermal fibroblasts. The system’s biology research was conducted in collaboration with a research team led by Professor Cho Kwang-hyun of the Department of Bio and Brain Engineering at KAIST. The result of the research was published in the online edition of an internationally renowned scientific journal, PNAS, on November 23. (The research article is titled “Inhibition of 3-phosphoinositide–dependent protein kinase 1 (PDK1) can revert cellular senescence in human dermal fibroblasts”.)

As skin cells get older, their ability to divide becomes significantly weakened, slowing down the speed of regeneration and the overall functionality of skin tissue. They also lose the ability to produce collagen and elastic fibers which, in turn, slows down skin regeneration making the skin thinner, and thus creating wrinkles. In addition, a weak skin barrier causes frequent dryness, itchy skin, and other troubles.

In this industry-university research collaboration, Amorepacific R&D Center and Professor Cho’s team developed a signaling network model for aging skin cells. The joint team ran simulations to analyze the model and discovered a core f that reverses aging in old cells and converts them into younger cells. Using this factor, the team managed to develop an original technology for reverse aging.

These findings are meaningful in that we have found the potential to reverse the biological phenomenon of aging in skin cells that was previously considered irreversible. When we regulated the activity of PDK1 (3-phosphoinositide–dependent protein kinase 1), the core factor that reverse aging, in the artificial model of aged skin, we found that PDK1 inhibition not only reverses the reduction in collagen synthesis, but also helps recover the skin’s ability to regenerate. It is expected that we can leverage this reverse aging technology to not only predict and suppress the progress of age-related diseases, but also to prolong the healthy years of our lives.

Park Won-seok, Director of Research & Innovation Center at Amorepacific R&D Center said, “The joint research enabled us to build an aging signal network model and an artificial model for aged skin, with which we saw the potential to reverse the aging process in the skin. Amorepacific will continue to build on our studies on dermatology and bio sector to slow down or improve the progress of aging that was previously thought impossible. We will continue to put in our utmost efforts to safeguard the health of our customers worldwide.”

Based on the results of the studies, Amorepacific R&D Center is developing cosmetics that reduce wrinkles by extracting a core ingredient in Camellia japonica seed extract that controls aging in human skin.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amorepacific-develops-an-original-technology-that-reverses-the-aging-of-skin-cells-in-joint-research-with-kaist-301180953.html

SOURCE Amorepacific

Posted on

A Vital Mandate, An Historic Opportunity

Vancouver Foundation congratulates Niki Sharma on being appointed Parliamentary Secretary for Community Development and Non-Profits and commends the Government of BC for showing national leadership when it’s needed more than ever

VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) — With almost one quarter of BC charities and nonprofits at risk of closing their doors as a result of COVID-19, Vancouver Foundation CEO Kevin McCort congratulates Niki Sharma on being appointed Parliamentary Secretary for Community Development and Non-Profits — and applauds Premier Horgan for the Government of BC’s commitment to acknowledging the important role of charities and nonprofits.

This appointment comes at a critical time. BC’s charities and nonprofit are under threat just when the need is greatest. Data from a survey released earlier this year revealed 23% of charities and nonprofits said they’re at risk of closing their doors because of urgent threats caused by the pandemic — even as demand for their services is rising.

These organizations have been on the frontlines of providing critical services and maintaining resiliency throughout each wave of the virus. But now, with revenue and income shrinking, their very existence is at risk. We need quick action and close coordination to ensure they can continue to fill the gaps between the roles of government and the private sector as we all pull together to weather this storm. Vancouver Foundation is pleased to see the Government of BC take concrete action to build this relationship.

Vancouver Foundation is excited to collaborate with the new Parliamentary Secretary to engage charities and nonprofits in key elements of the government’s Stronger BC recovery plan: a nimble workforce, expanded community infrastructure, and wraparound supports like childcare, mental health services, and food security initiatives. With this appointment the government is saying it understands the critical contribution this sector makes to the wellbeing of people and communities across the province.

Beyond addressing the urgency of this crisis, there’s an even greater opportunity to leverage a crucial sector that contributes $6.7 billion to BC’s GDP, employs 86,000 British Columbians, and serves tens of thousands more each year. Dire challenges like the overdose crisis, racial justice, and climate change demand greater collaboration between sthe provincial government and the nonprofit sector to harness existing know-how and foster innovation.

This is an historic opportunity to foster new types of partnerships, mobilize new resources, and maximize the potential of the third sector for improving economic, social, and environmental outcomes. Vancouver Foundation applauds the Premier for seeing the potential of working together in new ways — and for appointing a Parliamentary Secretary with strong community credentials to lead this vital work.

Quote
s

Kevin McCort, President & CEO of Vancouver Foundation

“
Today’s historic appointment comes at an urgent time. This pandemic is hurting
the many people who rely on
charities and nonprofits in communities across BC — and our
province
can’t recover without the vital services and supports the
se organizations
deliver. We’re ready to hit the ground running and excited to work with
Parliamentary Secretary Sharma
to get this sector back on its feet,
harness its potential in new ways
, and build BC back stronger than ever.
”

Learn More

About Vancouver Foundation

Vancouver Foundation is Community Inspired. Our vision is to create healthy, vibrant and livable communities across BC. We do this by bringing together generous donors and linking their contributions to important work that addresses the needs of our communities. Vancouver Foundation is considered a local, regional, national, and international leader in responsive and proactive grantmaking and community capacity-building initiatives and collaborations. For a view into our world visit www.vancouverfoundation.ca.

Media Contact
:
Glenn Ewald, Director of Communications
     
Email:
Phone:		         [email protected]

604-629-2728
     



Posted on

Gensource Potash: Decision to Replace “Financial Investor”

Gensource Potash: Decision to Replace “Financial Investor”

SASKATOON, Saskatchewan–(BUSINESS WIRE)–
Gensource Potash Corporation (“Gensource” or the “Company”) (TSX-V:GSP), a fertilizer development company focused on sustainable potash production, announces that, in alignment with its partner and Tugaske Project off-taker, Helm AG, it has made the decision to replace the “financial investor” as identified in the Tugaske Project SPV (Special Purpose Vehicle).

In previous news releases, Gensource identified a financial investor in the structure diagrams for the project SPV. The SPV structure is not changing, only the specific unnamed group identified as the financial investor. The replacement is expected to originate from a group of parties that have already expressed interest in the project. This group includes both pure financial investors and groups with sector-specific experience. Sector-specific experience would, of course, add value to the SPV in addition to the pure financial investment.

The replacement will allow for a synergistic partnership that aligns with the vision for, and future operation of the Tugaske Project. It will help reduce project risk and help expedite project financing and execution.

Mike Ferguson, President & CEO of Gensource said, “Consistent with our focus on transparency, Gensource is pleased to share this update with its shareholders. It represents a positive incremental evolution of the project SPV and Gensource looks forward to working with Helm to create this new partnership and to the continued progress of the Tugaske project… meanwhile, the Gensource-Helm team continue to work through the senior debt and Euler Hermes processes.”

About Gensource

Gensource Potash is a fertilizer development company based in Saskatoon, Saskatchewan and is on track to become the next fertilizer production company in that province. With a small scale and environmentally leading approach to potash production, Gensource believes its technical and business model will be the future of the industry. Gensource operates under a business plan that has two key components: (1) vertical integration with the market to ensure that all production capacity built is directed, and pre-sold, to a specific market, eliminating market-side risk; and (2) technical innovation which will allow for a small and economic potash production facility, that demonstrates environmental leadership within the industry, producing no salt tailings, therefore eliminating decommissioning risk, and requiring no surface brine ponds, thereby removing the single largest negative environmental impact of conventional potash mining.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This news release may contain forward looking information and Gensource cautions readers that forward- looking information is based on certain assumptions and risk factors that could cause actual results to differ materially from the expectations of Gensource included in this news release. This news release includes certain “forward-looking statements”, which often, but not always, can be identified by the use of words such as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. These statements are based on information currently available to Gensource and Gensource provides no assurance that actual results will meet management’s expectations. Forward looking statements include estimates and statements with respect to Gensource’s future plans, objectives or goals, to the effect that Gensource or management expects a stated condition or result to occur, including the ability to finance the Tugaske Project or other projects, the establishment of vertical integration partnerships and the sourcing of end use potash purchasers. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to Gensource’s financial condition and prospects, the ability to finance the Tugaske Project or other projects on terms which are economic or at all, the ability to establish viable vertical integration partnerships and the sourcing of end use potash purchasers could differ materially from those currently anticipated in such statements for many reasons such as: failure to finance the Tugaske Project or other projects on terms which are economic or at all; failure to settle a definitive joint venture agreement with a party and advance and finance the project; changes in general economic conditions and conditions in the financial markets; the ability to find and source off-take agreements; changes in demand and prices for potash; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological and operational difficulties encountered in connection with Gensource’s activities; and other matters discussed in this news release and in filings made with securities regulators. This list is not exhaustive of the factors that may affect any of Gensource’s forward-looking statements. These and other factors should be considered carefully, and readers should not place undue reliance on Gensource’s forward-looking statements. Gensource does not undertake to update any forward-looking statement that may be made from time to time by Gensource or on its behalf, except in accordance with applicable securities laws.

Gensource Potash Corporation:

Mike Ferguson, President and CEO

Telephone: (306) 974-6414

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Agriculture Natural Resources Other Natural Resources

MEDIA:

Logo
Logo
Posted on

Antera Ventures I Corp. and Wishpond Technologies Ltd. Announce Receipt of TSXV Conditional Approval and Filing of Filing Statement

Canada NewsWire

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, Nov. 26, 2020 /CNW/ – Antera Ventures I Corp. (TSXV: ANTI.P) (the “Company“) is pleased to announce that the TSXV Venture Exchange (“TSXV“) has conditionally approved its proposed business combination with Wishpond Technologies Ltd. (“Wishpond“) by way of a three-cornered amalgamation which will constitute the qualifying transaction of the Company (the “Qualifying Transaction“), and that it has filed a filing statement in respect of the Qualifying Transaction dated effective November 26, 2020 on the Company’s SEDAR profile.

Assuming all conditions to the closing of the Qualifying Transaction are satisfied, the Company and Wishpond anticipate closing the Qualifying Transaction on or about December 8, 2020. In due course, the parties will issue a further press release announcing the closing of the Qualifying Transaction and the date on which the common shares of the Company will resume trading.

In connection with the Qualifying Transaction, and prior thereto, the Company will change its name to “Wishpond Technologies Ltd.” and consolidate its outstanding share capital on the basis of approximately 4.646720625 (old) common shares for 1 (new) common share. In addition, an aggregate of 6,133,000 subscription receipts of Wishpond will be converted into Wishpond common shares immediately prior to the completion of the Qualifying Transaction, and all shares of Wishpond will be exchanged for (new) common shares of the Company at the effective time of the Qualifying Transaction on the basis of approximately 3.2439938 (new) common shares of the Company for each 1 Wishpond share.

Additional Information

The Qualifying Transaction is not a “Non-Arm’s Length Transaction” (as defined in the Policies of the TSXV), and as such shareholder approval is not required for the Qualifying Transaction under the Policies of the TSXV.

Trading in the common shares of the Company is presently halted and will remain halted until completion of the Qualifying Transaction.

Completion of the Qualifying Transaction is subject to a number of conditions and there can be no assurance that the Qualifying Transaction will be completed as proposed or at all.

For further information, please refer to the Filing Statement posted to the Company’s issuer profile on SEDAR at www.sedar.com, as well as the press releases of the Company dated July 27, 2020, September 14, 2020 and October 15, 2020.

About Wishpond Technologies Ltd.

Wishpond is a provider of marketing focused online business solutions based out of British Columbia. Wishpond offers an “all-in-one” marketing suite that provides companies with marketing, promotion, lead generation and sales conversion capabilities. Wishpond replaces entire marketing functions in an easy to use platform, for a fraction of the cost. Wishpond serves over 2,000 customers who are primarily small-to-medium size businesses (SMBs) in a wide variety of industries.

Wishpond’s vision is to become the leading provider of digital marketing solutions that empower entrepreneurs to achieve success online, regardless of their industry or size. Wishpond has developed cutting edge marketing technology solutions and continues to add new features and applications with great velocity. In addition to offering specific lead generation tools, Wishpond also provides advanced marketing applications integrated and managed from a centralized platform.

Wishpond employs a subscription-based SaaS (Software as a Service) model where customers subscribe to the company’s software and services through annual or monthly recurring plans. Substantially all of the company’s revenue is subscription based recurring revenue which provides excellent revenue and cash flow visibility.

About Antera Ventures I Corp.

Antera is a capital pool company created pursuant to the policies of the TSXV. It does not own any assets, other than cash or cash equivalents and its rights under the Definitive Agreement. The principal business of Antera is to identify and evaluate opportunities for the acquisition of an interest in assets or businesses and, once identified and evaluated, to negotiate an acquisition or participation subject to acceptance by the TSXV so as to complete a qualifying transaction in accordance with the policies of the TSXV.

Completion of the Qualifying Transaction is subject to a number of conditions, including TSXV acceptance. There can be no assurance that the Qualifying Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Qualifying Transaction, any information released or received with respect to the Qualifying Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the Qualifying Transaction and has neither approved nor disapproved the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can frequently, but not always, be identified by use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events, conditions or results “will”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotations thereof. All statements other than statements of historical fact may be forward-looking statements. Forward looking-information in this news release includes, but is not limited to, statements with respect to the completion of the Qualifying Transaction and the transactions related therein, satisfaction of the conditions to the closing of the Qualifying Transaction, the anticipated closing date of the Qualifying Transaction, the resumption of the trading of the common shares of the Company, the issuance of common shares of the Company in exchange for shares of Wishpond, and the receipt of all applicable regulatory approval in a timely manner or at all. Such forward-looking information is subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by the forward-looking information, such as the risk that the conditions to closing of the Qualifying Transaction will not be satisfied in a timely manner or at all, that the Company will not be able to complete the Qualifying Transaction, and that the Company will not receive all applicable regulatory approvals in a timely manner or at all. Although the Company has attempted to identify important factors that would cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. The statements in this news release are made as of the date of this release.

SOURCE Antera Ventures I Corp.